New online calculator launched to determine risk of spread of melanoma
15 June 2020
Clinicians around the world now have access to a new online calculator that predicts the risk that a patient’s primary melanoma has spread to nearby lymph nodes.
For patients recently diagnosed with melanoma, one of the first hurdles is to find out whether the melanoma cells have spread. To do this, clinicians will biopsy the first lymph node (known as the “sentinel” node) to see if melanoma cells are present, indicating that spread to it has occurred. If it has, it greatly increases the likelihood that it has spread further. This information in turn, helps determine the patient’s best treatment plan.
Dr Alexander Varey and Associate Professor Serigne Lo from Melanoma Institute Australia, whose team developed the calculator based on research published today in the Journal of Clinical Oncology, said it has the potential to better identify melanoma patients who are most likely to benefit from a sentinel node biopsy, as well as those least likely to benefit.
‘For us, one of the big questions was, can we better predict which patients will be at significant risk of having their cancer spread to their lymph nodes?’ said Dr Varey. ‘That’s what this calculator aims to do.
‘The calculator takes into account five pieces of basic information about the melanoma and the patient’s age to determine the patient’s individual risk of the cancer having spread to their lymph nodes.
‘This means that patients deemed at low risk of disease spread can potentially avoid having a sentinel node biopsy, which sometimes has complications and usually requires a general anaesthetic.’
Current treatment guidelines recommend that if a patient has a tumour with a particular set of parameters – mainly tumours that are slightly thicker or ulcerated – then removal and examination of the sentinel node should be considered. However, these guidelines are not tailored to individual patients and don’t take into account important information including the age of the patient. Younger age is known to be one of the most important risk factors for melanoma spreading to lymph nodes.
Supported by a Sydney Health Partners grant, the MIA team used established international calculators as a starting point. The research team tailored them to Australian demographics using patient data from Melanoma Institute Australia’s extensive database, which has been built up over a 50-year period. The team then built a new calculator to include additional patient parameters that increased its reliability and showed it provided considerably more accurate predictions than were previously available.
The calculator has been trialed at sites including Royal Prince Alfred, Royal North Shore and Westmead Hospitals with enthusiastic responses from clinicians and their patients.
‘The calculator enables clinicians to have better informed discussions with their patients based on each individual’s percentage risk, rather than a few simplistic criteria that only approximate the risk of disease spread to the lymph nodes,’ said MIA Co-Medical Directors, Professor Richard Scolyer and Professor Georgina Long AO.
‘The main benefit of the calculator is likely to be for those deemed to be at low risk of disease spread, who can safely forgo a sentinel node biopsy. This is of benefit particularly to older patients who are less likely to have melanoma spread to their lymph nodes, but who are at increased risk of complications from extra surgery and general anaesthesia.’
The Sentinel Node Biopsy Risk Calculator is available for clinician use here: www.melanomarisk.org.au
An improved risk-prediction calculator for sentinel node positivity in melanoma patients: the MIA nomogram.
Serigne N Lo, Jiawen Ma, Richard A Scolyer, Lauren E Haydu, Jonathan R Stretch, Robyn PM Saw, Omgo E Nieweg, Kerwin F Shannon, Andrew J Spillane, Sydney Ch’ng, Graham J Mann, Jeffrey E Gershenwald, John F Thompson, Alexander HR Varey.
Published in: Journal of Clinical Oncology
A message from our CEO, Carole Renouf
Piction, Brisbane, Bahturst and Port Macquarie march to end melanoma.
Australian researchers have greater clarity on the best course of treatment for patients with advanced melanoma which has spread to the brain.
Melanoma treatment has come a long way in recent times, and the role that nurses play caring for melanoma patients has changed dramatically too.
It was a massive weekend of Melanoma Marches with six Marches in: Bendigo, Canberra, Manly, Newcastle, Bunbury and Adelaide.
Weekend two hit the ground marching with Melanoma Marches in Wollongong, Townsville, Mandurah and Western Sydney.
Melanoma Institute Australia's annual fundraising initiative is all systems go!
The reported proliferation of illegal commercial solariums is costing lives and requires urgent government intervention.
15-year-old melanoma survivor Toby Rayner will lead Mount Gambier’s march against melanoma Julie-Ann Sams knows all too well that melanoma doesn’t discriminate.
Updated guidelines defining appropriate excision margins have been published thanks to research from MIA.
Joanne and her trusty companion Frankie spend their days spreading a message of hope in hospitals, nursing homes, even prisons. It is a long way from her darkest hour facing palliative care. This is her story of hope.
Melanoma impacts more Australian teenagers and young adults than any other cancer. Dr James Wilmott, who has a young family of his own, has devoted his career to determining why these young Australians are susceptible to melanoma, and importantly, how to save them.
Melanoma Masterclass celebrates Australian luminaries who have transformed melanoma treatment worldwide
The extraordinary contribution of Australia’s most distinguished melanoma clinicians and researchers is being celebrated today.
Congratulations to Professor Richard Scolyer who was awarded the William O. Russell/Joanne Vandenberge Hill Award of Excellence in Pathology.
A Day in the Life Of... Serigne Lo, Research and BioStatistics Manager at Melanoma Institute Australia
Jay was your typical Aussie bloke – a truck driver, husband, dad and mate to many. Then he got melanoma. His cancer diagnosis turned his life upside down.
Clair faced an impossible choice – risk delivering her baby early, or delay potentially life-saving melanoma treatment
Little Madi misses her Dad. But she is determined to honour his memory and support life-saving melanoma research.
Toyota and country music fans invited to tip their hat to help tackle Australia's national cancer – melanoma
Melanoma Institute Australia has teamed up with the Toyota Country Music Festival 2018 in Tamworth!